The disclosure relates to a tissue adhesive for use in a treatment method in which an ophthalmological implant is implanted in a human or animal patient and the ophthalmological implant is connected, at least partially in an integrally bonded manner, to eye tissue of the patient via the tissue adhesive. The disclosure also relates to an ophthalmological implantation system including an ophthalmological implant for implantation in a human or animal eye and to a tissue adhesive via which the ophthalmological implant is connectable, at least partially in an integrally bonded manner, to eye tissue of the patient.

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

##STR00001##

Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

##STR00001##

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

The present disclosure provides a method of treating cardiometabolic syndrome (CMS) with a GDF15 molecule. Also provided herein is a method of treating a cardiac or heart condition. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region, optionally via a linker.